Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2017

Open Access 01-12-2017 | Case report

Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies

Authors: Olimpia Sipak-Szmigiel, Piotr Włodarski, Elżbieta Ronin-Walknowska, Andrzej Niedzielski, Beata Karakiewicz, Sylwia Słuczanowska-Głąbowska, Maria Laszczyńska, Witold Malinowski

Published in: Journal of Ovarian Research | Issue 1/2017

Login to get access

Abstract

Background

Although immune system plays a key role in the pathogenesis of both endometriosis and ovarian cancer, its function is different. Therefore, we hypothesized, that selected immune parameters can serve as diagnostic markers of these two conditions. The aim of this study was to compare serum and peritoneal fluid concentrations of sHLA-G, IL-10 and TNF-alpha in women with selected ovarian pathologies: benign serous cysts, endometrioma and malignant tumors. Clinical significance of using them for diagnostic purposes in women with serous ovarian cysts, endometriosis, and ovarian cancer, which in the future may improve the early diagnosis of ovarian diseases.

Case Presentation

The study included women treated surgically for benign serous ovarian cysts, ovarian endometrioma and serous ovarian adenocarcinomas. Peripheral blood and peritoneal fluid samples were obtained intraoperatively.
Patients with benign serous cysts, endometrioma and ovarian malignancies did not differ significantly in terms of their serum and peritoneal fluid concentrations of sHLA-G. Ovarian cancer patients presented with significantly higher median serum concentrations of IL-10 and TNF-alpha than other study subjects. Median concentrations of IL-10 and TNF-alpha in peritoneal fluid turned out to be the highest in ovarian cancer patients, followed by women with endometrioma and subjects with benign serous cysts. All these intergroup differences were statistically significant. Irrespective of the group, median concentrations of sHLA-G, IL-10 and TNF-alpha in peritoneal fluid were higher than serum levels of these markers.

Conclusions

Elevated serum and peritoneal fluid concentrations of IL-10 and TNF-alpha distinguish ovarian malignancies and endometriomas from benign serous ovarian cysts. In contrast to endometriosis, ovarian malignancies are characterized by elevated peritoneal fluid concentrations of IL-10 and TNF-alpha, elevated serum concentrations of IL-10 and low serum levels of TNF-alpha. Serum and peritoneal fluid concentrations of sHLA-G have no diagnostic value in differentiating between ovarian malignancies and endometriomas.
Literature
1.
2.
3.
Ulukus M, Arici A. Immunology of endometriosis. Minerva Ginecol. 2005;57:237–48.PubMed
4.
Chung EY, Liu J, Homma Y, Zhang Y, Brendolan A, Saggese M, et al. Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity. 2007;27:952–64.CrossRefPubMedPubMedCentral
5.
Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4:87–95.CrossRefPubMedPubMedCentral
6.
Aris A. Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res. 2010;3:1757–2215.CrossRef
7.
8.
Lee KS, Baek DW, Kim KH, Shin BS, Lee DH, Kim JW, et al. IL-10-dependent down-regulation of MHC class II expression level on monocytes by peritoneal fluid from endometriosis patients. Int Immunopharmacol. 2005;5:1699–712.CrossRefPubMed
9.
Hviid TV, Hylenius S, Hoegh AM, Kruse C, Christiansen OB. HLA-G polymorphisms in couples with recurrent spontaneous abortions. Tissue Antigens. 2002;60:122–32.CrossRefPubMed
10.
Kobayashi H, Higashiura Y, Shigetomi H, Kajihara H. Pathogenesis of endometriosis: the role of initial infection and subsequent sterile inflammation (Review). Mol Med Rep. 2014;9:9–15.PubMed
11.
Zheng XQ, Li CC, Xu DP, Lin A, Bao WG, Yang GS, et al. Analysis of the plasma soluble human leukocyte antigen-G and interleukin-10 levels in childhood atopic asthma. Hum Immunol. 2010;71:982–7.CrossRefPubMed
12.
13.
14.
15.
Canis M, Donnez J, Guzick D, Halme JRock J, Schenken R, et al. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67:817–21.CrossRef
16.
Sayed D, Badr G, Maximous D, Mikhail NN, Abu-Tarboush F, Alhazza IM. HLA-G and its relation to proliferation index in detection and monitoring breast cancer patients. Tissue Antigens. 2010;75:40–7.CrossRefPubMed
17.
18.
19.
Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005;65:10139–44.CrossRefPubMed
20.
Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003;9:4460–4.PubMed
21.
Mach P. The clinical significance of HLA-G in the context of gynecological cancer and conditions associated with pregnancy. Arch Perinatal Med. 2013;19:156–65.
22.
Basta P, Gałązka K, Stasienko E, Dutsch-Wicherek M, Wicherek Ł. Analysis of B7H4 and HLA-G immunoreactivity within ovarian cancer relapse and its microenvironment according to the preceding applied chemotherapy. Curr Gynecol Oncol. 2011;9:9–17.
23.
Matalliotakis IM, Athanassakis I, Goumenou AG, Neonaki MA, Koumantakis EE, Vassiliadis S, et al. The possible anti-inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot. Mediators Inflamm. 2001;10:75–80.CrossRefPubMedPubMedCentral
24.
Eidukaite A, Tamosiunas V. Soluble HLA-G in the peritoneal fluid of women with endometriosis. Fertil Steril. 2008;89:465–7.CrossRefPubMed
25.
Barrier BF, Kendall BS, Ryan CE, Sharpe-Timms KL. HLA-G is expressed by the glandular epithelium of peritoneal endometriosis but not in eutopic endometrium. Hum Reprod. 2006;21:864–9.CrossRefPubMed
26.
Wang F, Wen Z, Li H, Yang Z, Zhao X, Yao X. Human leukocyte antigen-G is expressed by the eutopic and ectopic endometrium of adenomyosis. Fertil Steril. 2008;90:1599–604.CrossRefPubMed
27.
Hornung D, Fujii E, Lim KH, Vigne JL, McMaster MT, Taylor RN. Histocompatibility leukocyte antigen-G is not expressed by endometriosis or endometrial tissue. Fertil Steril. 2001;75:814–7.CrossRefPubMed
28.
Mach P, Blecharz P, Basta P, Marianowski P, Skret-Magierlo J, Kojs Z, et al. Differences in the soluble HLA-G blood serum concentration levels in patients with ovarian cancer and ovarian and deep endometriosis. Am J Reprod Immunol. 2010;63:387–95.CrossRefPubMed
29.
Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer. 1993;72:2433–40.CrossRefPubMed
30.
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012;72:66–75.CrossRefPubMed
31.
Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod. 2008;23:2017–23.CrossRefPubMedPubMedCentral
32.
Eisermann J, Gast MJ, Pineda J, Odem RR, Collins JL. Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. Fertil Steril. 1988;50:573–9.CrossRefPubMed
33.
Braun DP, Gebel H, House R, Rana N, Dmowski NP. Spontaneous and induced synthesis of cytokines by peripheral blood monocytes in patients with endometriosis. Fertil Steril. 1996;65:1125–9.CrossRefPubMed
34.
Rana N, Braun DP, House R, Gebel H, Rotman C, Dmowski WP. Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis. Fertil Steril. 1996;65:925–30.CrossRefPubMed
35.
Podgaec S, Dias Junior JA, Chapron C, Oliveira RM, Baracat EC, Abrao MS. Th1 and Th2 ummune responses related to pelvic endometriosis. Rev Assoc Med Bras. 1992;56:92–8.CrossRef
36.
Xavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, et al. Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet. 2006;273:227–31.CrossRefPubMed
37.
Zhang RJ, Wild RA, Ojago JM. Effect of tumor necrosis factor-alpha on adhesion of human endometrial stromal cells to peritoneal mesothelial cells: an in vitro system. Fertil Steril. 1993;59:1196–201.CrossRefPubMed
38.
39.
Bertazza L, Mocellin S. The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem. 2010;17:3337–52.CrossRefPubMed
40.
Galo S, Zubor P, Szunyogh N, Kajo K, Machalekova K, Biringer K, et al. TNF-alpha serum levels in women with endometriosis: prospective clinical study. Ceska Gynekol. 2005;70:286–90.PubMed
41.
Zhou J, Ye F, Chen H, Lv W, Gan N. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res. 2007;35:290–300.CrossRefPubMed
42.
Berger S, Siegert A, Denkert C, Kobel M, Hauptmann S. Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol Immunother. 2001;50:328–33.CrossRefPubMed
43.
Berek JS, Bast Jr RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, et al. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol. 1984;64:708–14.PubMed
44.
Mustea A, Konsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res. 2006;26:1715–8.PubMed
45.
Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer. 2011;47:1883–9.CrossRefPubMed
46.
Matte I, Lane D, Laplante C, Rancourt C, Piche A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res. 2012;2:566–80.PubMedPubMedCentral
47.
Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol. 2012;22:350–8.CrossRefPubMed
48.
Yoon BS, Kim YT, Kim JW, Kim SH, Kim JH, Kim SW. Expression of human leukocyte antigen-G and its correlation with interleukin-10 expression in cervical carcinoma. Int J Gynaecol Obstet. 2007;98:48–53.CrossRefPubMed
49.
Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993;178:2207–11.CrossRefPubMed
50.
Kanai T, Fujii T, Kozuma S, Yamashita T, Miki A, Kikuchi A, Taketani Y. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod. 2001;7:195–200.CrossRefPubMed
51.
Kleinberg L, Florenes V, Skrede M, Dong H, Nielsen S, McMaster M, et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006;449:31–9.CrossRefPubMed
52.
Ye S, Yang H, Li K, Dong D, Lin X, Yie S. Human leukocyte antigen G expresion: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20:375–83.CrossRefPubMed
53.
Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, Rouas-Freiss N, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Br J Hematol. 2007;138:202–12.CrossRef
54.
Gros F, Sebti Y, de Guiberty S, Branger B, Bernard M, Fauchet R, et al. Soluble HLA-G molecules are increased during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia. 2006;8:223–30.CrossRefPubMedPubMedCentral
Metadata
Title
Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies
Authors
Olimpia Sipak-Szmigiel
Piotr Włodarski
Elżbieta Ronin-Walknowska
Andrzej Niedzielski
Beata Karakiewicz
Sylwia Słuczanowska-Głąbowska
Maria Laszczyńska
Witold Malinowski
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2017
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-017-0320-9

Other articles of this Issue 1/2017

Journal of Ovarian Research 1/2017 Go to the issue

Research

MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression

Research

HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer

Research

Does the transfer of a poor quality embryo together with a good quality embryo affect the In Vitro Fertilization (IVF) outcome?

Case report

A gestational choriocarcinoma of the ovary diagnosed by DNA polymorphic analysis: a case report and systematic review of the literature

Research

The value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas

Research

Protective effects of GABA against metabolic and reproductive disturbances in letrozole induced polycystic ovarian syndrome in rats